BackScribe Therapeutics Overview
Scribe Therapeutics Inc.

Scribe Therapeutics Target Price

See Scribe Therapeutics's analyst price targets ($52) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$12.07

Average Target Price

$51.75328.7% upside

4 analysts in the last 4 months

High: $60 | Low: $37

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-31H.C. Wainwright$60397.1% upsideOpen
2026-08-18Leerink PartnersDavid Risinger$37206.5% upsideOpen
2026-08-18Guggenheim$50314.3% upsideOpen
2026-08-18Wells Fargo$60397.1% upsideOpen

Scribe Therapeutics (SCTX) FAQ

As of the most recent data, SCTX shows a target price of $52. Scroll down for historical charts and peer comparison views.

If Scribe Therapeutics moved to the average analyst target of $52, shares would be roughly 328.7% higher than $12.07. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Scribe Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Scribe Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $52) with ownership activity and broader fundamentals.

Scribe Therapeutics's target price is $52; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.

Questions & Answers